Cancer Research SABCS Genetics and Biology of Brain Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sasaki, M.
Right arrow Articles by Dahiya, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sasaki, M.
Right arrow Articles by Dahiya, R.
[Cancer Research 63, 3913-3918, July 15, 2003]
© 2003 American Association for Cancer Research

Advances in Brief

CYP1B1 Gene Polymorphisms Have Higher Risk for Endometrial Cancer, and Positive Correlations with Estrogen Receptor {alpha} and Estrogen Receptor ß Expressions

Masahiro Sasaki, Yuichiro Tanaka, Masanori Kaneuchi, Noriaki Sakuragi and Rajvir Dahiya1

Department of Urology, University of California San Francisco and Veterans Affairs Medical Center, San Francisco, California 94121 [M. S., Y. T., M. K., R. D.], and Department of Obstetrics and Gynecology, School of Medicine, Hokkaido University, Kitaku, Sapporo, Japan [N. S.]


   ABSTRACT
Top
 ABSTRACT
Introduction
 Materials and Methods
 Results
 Discussion
 REFERENCES
 
The estradiol metabolites by CYP1B1 received particular attention because of their causative role in malignant transformation of endometrium. We hypothesize that polymorphisms of CYP1B1 gene can predict higher incidence of endometrial cancer. To test this hypothesis, the genetic distributions of six different CYP1B1 gene polymorphisms were investigated, by sequence-specific PCR and direct DNA sequencing, in 113 Japanese endometrial cancer patients and 202 healthy controls. We also investigated whether the expression of estrogen receptors (ER{alpha} and ERß), progesterone receptor, and androgen receptor genes are influenced by the CYP1B1 genotypes in endometrial cancer. The results of our study demonstrated that the distributions of CYP1B1 genotypes at codons 119 and 432 were significantly different between endometrial cancer patients and healthy normal controls. The relative risks of 119T/T and 432G/G in endometrial cancer were calculated as 3.32 and 2.49 compared with wild-types. The 119T/T showed significant correlation for positivities of ER{alpha} and ERß. The 432G/G also showed weak correlations for ER{alpha} positivity. Other loci, intron 1, codon 48, and codon 449 were not different between endometrial cancer patients and healthy normal control.

This is the first report that demonstrates that the rare polymorphisms at codons 119 and 432 of CYP1B1 gene have higher risk for endometrial cancer, and positive correlations with ER{alpha} and ERß expressions in endometrial cancer.


   Introduction
Top
 ABSTRACT
 Introduction
Materials and Methods
 Results
 Discussion
 REFERENCES
 
Endometrial carcinoma is a common gynecological malignancy of the female urogenital tract, and its incidence is increasing significantly (1) . However, the genetic basis of this disease is not well understood. The metabolic conversion of estrogens to 4-hydroxy estrogens has been postulated to be a major factor in carcinogenesis (2 , 3) . CYP1B1 converts estrogens to 4-hydroxy estrogens that induce DNA damage (4 , 5) . 4-Hydroxy estrogens are shown to induce endometrial adenocarcinoma in mice (4) . CYP1B1 displays the highest level of expression in endometrial tissue (3) . These reports strongly suggest that the CYP1B1 gene is a key player in endometrial carcinogenesis (3, 4, 5) . Several studies have shown that polymorphisms in several genes such as CYP1B1 can induce hyperactivation of proteins and increase the incidence of several cancers (6, 7, 8) . Several polymorphisms of the CYP1B1 gene have been described of which four result in amino acid substitutions: intron 1–13C->T, codon 48 C->G, codon 119 G->T, codon 432 C->G, codon 449 T->C, and codon 453 A->G (9, 10, 11) . Intron 1 contains a polymorphic site at nucleotide -13, exon 2 contains two polymorphic sites at codons 48 and 119, and exon 3 contains three polymorphic sites at codons 432, 449, and 453. Of the six polymorphisms in the CYP1B1 gene, amino acid replacements occur at codons 48, 119, 432, and 453 leading to the replacement of Arg -> Gly, Ala -> Ser, Leu -> Val, and Asn -> Ser, respectively. The polymorphisms on exons 2 and 3 have significant effects on the catalytic function of CYP1B1 (8 , 9) . The 4-hydroxylation activities of the variant enzymes, especially polymorphisms on codons 119 and 432, were 2–4-fold higher than the wild-type enzyme (8 , 9) . Because the CYP1B1 polymorphisms are inherited, they will dictate exposure levels of these estrogen metabolites during the lifetime of an individual (8 , 9) . Thus, inherited alterations in the activity of CYP1B1 leads to differences in estrogen metabolism and thereby, may possibly explain interindividual differences in endometrial cancer risk associated with estrogen-mediated carcinogenesis (8 , 9) . A recent study has shown significant correlations between 432G/G and ER{alpha}2 and PR positivity in breast cancer (9) . We hypothesize that polymorphisms of the CYP1B1 gene and activation of steroid receptors are important in pathogenesis of endometrial cancer. The present study was designed to investigate six polymorphisms on the CYP1B1 gene in endometrial cancer. We additionally investigated whether expression of steroid receptors, ER{alpha}, ERß, PR, and AR are influenced by CYP1B1 polymorphisms.


   Materials and Methods
Top
 ABSTRACT
 Introduction
 Materials and Methods
Results
 Discussion
 REFERENCES
 
Samples.
DNA from 113 sporadic endometrial cancer patients was obtained from the Department of Gynecology at the hospital of Hokkaido University (Hokkaido, Japan) between 1992 and 2000 (age range, 29–87 years; mean age, 61.7). The histopathological types of these cancers were as follows: 86 of endometrioid cancer, 6 of adenoacantoma, 2 of adenosquamous cancer, 2 of clear cell cancer, and 17 of unknown type. Cancer-free control samples were obtained from 202 unrelated Japanese healthy volunteers in the same prefecture (100 women and 102 men, age range, 35–69 years; mean age, 59.3) at the same time period as endometrial cancer patient samples. Because no patients and healthy controls of other ethnic groups were recruited, this study was limited to a Japanese population. There were no differences between patients and control groups in regard to age, race, family history of cancer, indices of body size (height, weight, and body mass index), or income. Appropriate informed consent was obtained from the patients in accordance with local ethical committee guidelines of the hospital.

CYP1B1 Gene Polymorphisms.
For the analysis of CYP1B1 polymorphisms, a two-step PCR procedure was designed. A region covering the polymorphic sites in each exon was amplified in the first PCR followed by single nucleotide polymorphism-specific second PCR. In the first PCR, DNA was amplified using 10 ng DNA, 1.5 mM MgCl2, 0.8 mM deoxynucleotide triphosphate, 0.5 units of Taq polymerase (Applied Biosystems Inc., Foster City, CA), and specific first PCR primer sets (Table 1)Citation . The first PCR product was subsequently used as a template in the second PCR. Each polymorphic fragment from first PCR was amplified with 1.5 mM MgCl2, 0.8 mM deoxynucleotide triphosphate, 0.5 units of Taq polymerase, and specific second PCR primer sets. Each second PCR product (8 µl) was mixed with 1 µl of 10x loading dye and then run on 3% agarose gels. The bands on the gels were visualized by ethidium bromide staining. DNA samples with homozygous wild-type and mutated-type genotypes were used as controls to ensure nonspecific amplifications or PCR failures. Blank DNA controls were used to rule out PCR contamination, and ambiguous results were repeated until a clear result was obtained. For confirmation of genotyping, the PCR products were subjected to direct sequence. The PCR products were first purified by QIAquick PCR Purification kit (Qiagen, Valencia, CA). Then, a double-strand sequence analysis of the PCR products was performed using first PCR primer and ABI 377 Sequencer and Dye Terminator Cycle sequencing kit (Applied Biosystems Inc.; Ref. 12 ).


View this table:
[in this window]
[in a new window]

  		Table 1 Summary of the primer sets and SSP conditions for CYP1B1 polymorphisms

 
Immunohistochemistry.
Ninety-three endometrial cancer tissues from 113 endometrial cancer patients were also used for the immunohistochemical analysis by blinded procedure. Anti-ER{alpha}, -ERß, -PR, and -AR antibodies (F10, N19, C-19, and 441, respectively; Santa Cruz Biotech, Santa Cruz, CA) were used to identify the expression of these receptors in cancerous endometrium by standard immunohistochemical techniques (12) . Paraffin-embedded, endometrial cancer blocks were cut into 4-µ sections and dried at room temperature. After deparaffinization and rehydration, sections were treated with 2% hydrogen peroxidase in methanol for 20 min to inactivate endogenous peroxidase. Antigen retrieval was done by autoclaving (18 PSI) for 5 min in an antigen unmasking solution (Vector, Burlingame, CA). After blocking with 3% normal goat serum for 15 min, sections were incubated with each primary antibody at a 1:100 dilution with 5% goat serum in PBS overnight at 4°C under a humid chamber. Sections were washed with a solution containing 20 mM Tris, 150 mM NaCl, and 0.025% Tween (pH 7.8), and then incubated with secondary antibodies for 20 min. Immunostaining was done by using an avidin-biotin-peroxidase method (Lab Vision, Fremont, CA) with diaminobenzidine as the chromagen, followed by counterstaining with hematoxylin.

Statistical Analyses.
{chi}2 analysis was used to test deviation of genotype distributions from Hardy-Weinberg equilibrium (1 , 12) . The relative risk of endometrial cancer associated with each genotype was analyzed compared with female control group by calculating odds ratios with 95% CIs. Subsequent analysis included logistic regression analyses, adjusting for the potential confounding factors (age, height, weight, and body mass index). Homogeneity was tested as described previously (1 , 12) . {chi}2 and t tests, all two-sided, were used to analyze data for statistical significance (1 , 12) .


   Results
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results
Discussion
 REFERENCES
 
The structure of CYP1B1 gene and locations of six different polymorphic loci are shown in Fig. 1ACitation . Fig. 1BCitation shows representative samples of genotyping for intron 1 and codons 48, 119, 432, 449, and 453 of CYP1B1 gene in endometrial cancer patients. The frequency of distribution of the six genetic polymorphisms of CYP1B1 in endometrial cancer patients and the control group are shown in Table 2Citation . No difference was observed for the distributions of any polymorphic loci between men and women in normal control (Table 2A)Citation . The polymorphism on codon 453 was not detected in either the control group or the patient group, i.e., all of the individuals tested in this study were homozygous A for codon 453.



View larger version (70K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 1. A, schematic representation of the CYP1B1 gene structure. CYP1B1 gene at 2p21–22 is ~10 kb long and contains three exons. The open reading frame starts in the second exon and is 1629 bp in length, encoding a protein of 543 amino acids. Intron 1 contains a polymorphic site at nucleotide -13, exon 2 contains two polymorphic sites at codons 48 and 119, and exon 3 contains three polymorphic sites at codons 432, 449, and 453 (arrows). Four of the polymorphisms result in amino acid changes at codons 48 (Arg->Gly), 119 (Ala->Ser), 432 (Leu->Val), and 453 (Asn->Ser). B, the genotyping for intron 1, and codons 48, 119, 432, 449, and 453 of CYP1B1 in endometrial carcinoma patients. Lanes 1–3, C/C, C/T, and T/T at intron 1; Lanes 4–6, C/C, C/G, and G/G at codon 48; Lanes 7–9, G/G, G/T, and T/T at codon 119; Lanes 10–12, C/C, C/G, and G/G at codon 432; Lanes 13–15, C/C, T/C, and T/T at codon 449; Lanes 16–18, A/A, A/G, and G/G at codon 453; and Lane M: 25-bp ladder marker. C, typical results of genotyping, DNA sequencing, and immunohistochemical staining of patients with 119T/T and 119G/G. Left panels: the genotyping of six polymorphic loci of CYP1B1. Lane 1, intron 1; Lane 2, codon 48; Lane 3, codon 119; Lane 4, codon 432; Lane 5, codon 449; Lane 6, codon 453; and Lane M: 100-bp ladder marker. Center panels: DNA sequence of 119T/T and 119G/G samples. The arrows show homozygous T and G of codon 119. Right panels show protein expression of ER{alpha} and ERß of 119T/T and 119G/G samples. A cancer patient with 119T/T gene showed a strong staining pattern of ER{alpha} and ERß, although a cancer patient with 119G/G showed no staining of ER{alpha} and ERß.

 

View this table:
[in this window]
[in a new window]

  		Table 2 Six polymorphisms of CYP1B1 gene in endometrial cancer

 
The distributions of genotypes on codons 119 and 432 were significantly different between endometrial cancer patients and control (P < 0.001; Table 2BCitation ). 14.2% of endometrial cancer patients showed the 119T/T, although 6.0% of female controls showed this genotype. Of endometrial cancer patients, 42.5% showed 119G/T compared with 19.0% of female controls. The relative risks of 119T/T and 119G/T were calculated as 3.32 and 2.45 as compared with wild-type, respectively. On codon 432, 15.0% of endometrial cancer patients showed the 432G/G, whereas 7.0% of female controls showed this genotype. Of cancer patients, 34.5% showed genotype C/G, although 24.0% of female controls showed this genotype. The relative risks of 432G/G and 432C/G were calculated as 2.49 and 1.57 compared with wild-type, respectively. Other loci, intron 1, codon 48, and codon 449, were not different between endometrial cancer patients and normal healthy control. Table 2CCitation shows combined analysis of 119–432 genotypes for endometrial cancer (Table 2C)Citation . There are several samples with genotype of 119G/G-432C/G, 119T/T-432C/G, 119G/T-432C/C, and 119G/T-432G/G. Thus, codons119 and 432 are not in linkage disequilibrium (Table 2C)Citation . The relative risks for samples that have both 119T and 432G were much higher compared with samples with 119G/G-432C/C (Table 2C)Citation .

Table 2DCitation shows the correlation of the six polymorphisms of CYP1B1 with clinical stage of endometrial cancers. The 119T/T showed a significant correlation with higher stages (>stage 3) of endometrial cancer (P < 0.05; Table 2CCitation ). Of samples, 25.7% had 119T/T at higher stages (>stage 3), whereas 8.3% of samples were at lower stages (<stage 2). No significant correlations were found in any of the polymorphisms of CYP1B1 with pathological types of cancer, age, family history of cancer, height, weight, and body mass index, or income of the patients (data not shown).

The correlation of each CYP1B1 genotype with steroid receptor expression in endometrial cancer tissues is shown in Table 3Citation . The 119T/T showed a significant correlation with ER{alpha} and ERß positivities. Of samples, 93.3% with 119T/T were ER{alpha}-positive, whereas 55.3% of samples with 119G/G showed ER{alpha} positivity (P < 0.001; Table 3Citation ). Of samples, 40.0% with 119T/T were ERß-positive compared with 2.6% of samples with 119G/G (P < 0.001). The 432G/G also showed correlations for ER{alpha} positivities (P < 0.025; Table 3Citation ). Fig. 1CCitation shows typical results of genotyping at six polymorphic regions of CYP1B1 gene, direct sequencing, and immunostaining data for ER{alpha} and ERß in endometrial cancer patients with 119T/T and 119G/G (Fig. 1C)Citation . The ER{alpha} and ERß proteins were strongly positive in a patient with 119T/T, whereas they were negative in a patient with 119G/G.


View this table:
[in this window]
[in a new window]

  		Table 3 Correlation between CYP1B1 genotypes and steroid receptor expressions

 

   Discussion
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results
 Discussion
REFERENCES
 
The human CYP1B1 gene, located at the 2p21–22 region, consists of three exons (one of which is noncoding) and two introns (3 , 11, 12, 13) . The expression of CYP1B1 and the formation of 4-hydroxy estrogens have been associated with estrogen-related tumors in multiple tissues and species (4, 5, 6, 7 , 14, 15, 16) . Elevated 4-hydroxy estrogen production has been associated with carcinogenesis of various cancers including endometrial cancer (1 , 3 , 5 , 9 , 14 , 17) .

In the present study, significant differences in the allelic distributions of the codon 119 and codon 432 of CYP1B1 were found between endometrial cancer patients and healthy controls. The relative risks of 119T/T and 432G/G were significantly higher when compared with the wild-type. Moreover, we found a significant correlation between the 119T/T and higher stages of endometrial cancer. These data clearly demonstrate an association between the susceptible genotypes on exons 2 and 3 of CYP1B1 and endometrial cancer. In this regard, Hanna et al. (8) observed that polymorphic variants on exons 2 and 3 of CYP1B1 display a much stronger estrogen hydroxylation activity than wild-type in breast cancer (18) . These results indicate that polymorphisms on exons 2 and 3 modify enzymatic activity, thus increasing risk of developing endometrial and breast cancer because CYP1B1 expression is particularly high in these cancers (4 , 8 , 14 , 17) . When treating MCF-7 breast cancer cells with 4-hydroxy estrogens, the rate of cell proliferation and the expression of estrogen-inducible genes were increased (4 , 8 , 14 , 17) . In addition, 4-hydroxy estrogens can undergo redox cycling that result in the formation of free radicals such as superoxide and in the generation of reactive semiquinones/quinone intermediates that have been shown to damage biological target molecules such as DNA (14 , 15) . Exon 1 of the human CYP1B1 gene is noncoding, and no polymorphism has been identified in it. The polymorphism in intron 1 is located 13 nucleotides upstream of the 5'-end of exon 2 and is, therefore, unlikely to affect enzyme activity. The polymorphism at codon 449 is silent, because the amino acid sequence is not affected by this mutation (9 , 10) . It seems unlikely that polymorphisms other than those in codons 48, 119, 432, and 453 are present in the coding region (9 , 10 , 18) .

The 119T/T also showed a significant correlation for ER{alpha} and ERß positivities. Previous studies have shown that genotype 432G/G has a positive correlation with ER and PR expression in breast cancer, although some studies have shown no association between this polymorphism and breast cancer risk (8 , 9 , 19) . In other studies, treatment of MCF-7 breast cancer cells with 4-hydroxy estrogens increased the rate of cell proliferation and the expression of estrogen-inducible genes such as ER and PR (20) .

This is the first report to show that codons 119 and 432 polymorphisms on the CYP1B1 gene may have higher risk of endometrial cancer. The results of these experiments are important in understanding the role of CYP1B1 polymorphisms and activation of ERs in the pathogenesis of endometrial cancer.


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 To whom requests for reprints should be addressed, at Urology Research Center (112F), University of California San Francisco and Veterans Affairs Medical Center, 4150 Clement Street, San Francisco, CA 94121. Phone: (415) 750-6964; Fax: (415) 750-6639; E-mail: Urologylab{at}aol.com Back

2 The abbreviations used are: ER, estrogen receptor; PR, progesterone receptor; AR, androgen receptor; CI, confidence interval. Back

Received 2/ 4/03. Accepted 6/ 2/03.


   REFERENCES
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results
 Discussion
 REFERENCES
 

  1. Sasaki M., Kotcherguina L., Dharia A., Fujimoto S., Dahiya R. Cytosine-phosphoguanine methylation of estrogen receptors in endometrial cancer. Cancer Res., 61: 3262-3266, 2001.[Abstract/Free Full Text]
  2. Liehr J. G. Genotoxic effects of estrogens. Mutat. Res., 238: 269-276, 1990.[Medline]
  3. Hayes C. L., Spink D. C., Spink B. C., Cao J. Q., Walker N. J., Sutter T. R. 17ß-estradiol hydroxylation catalyzed by human cytochrome P450 1B1. Proc. Natl. Acad. Sci. USA, 93: 9776-9781, 1996.[Abstract/Free Full Text]
  4. Newbold R. R., Liehr J. G. Induction of uterine adenocarcinoma in CD-1 mice by catechol estrogens. Cancer Res., 60: 235-237, 2000.[Abstract/Free Full Text]
  5. Han X., Liehr J. G. DNA single-strand breaks in kidneys of Syrian hamsters treated with steroidal estrogens: hormone-induced free radical damage preceding renal malignancy. Carcinogenesis (Lond.), 15: 997-1000, 1994.[Abstract/Free Full Text]
  6. Meyer U. A., Gut J., Kronbach T., Skoda C., Meier U. T., Catin T. The molecular mechanisms of two common polymorphisms of drug oxidation—evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation. Xenobiotica, 16: 449-464, 1986.[Medline]
  7. Kawajiri K., Watanabe J., Eguchi H., Hayashi S. Genetic polymorphisms of drug-metabolizing enzymes and lung cancer susceptibility. Pharmacogenetics, 5: 70-73, 1995.
  8. Hanna I. H., Dawling S., Roodi N., Guengerich F. P., Parl F. F. Cytochrome P450 1B1 (CYP1B1) pharmacogenetics: association of polymorphisms with functional differences in estrogen hydroxylation activity. Cancer Res., 60: 3440-3444, 2000.[Abstract/Free Full Text]
  9. Bailey L. R., Roodi N., Dupont W. D., Parl F. F. Association of cytochrome P450 1B1 (CYP1B1) polymorphism with steroid receptor status in breast cancer. Cancer Res., 58: 5038-5041, 1998.[Abstract/Free Full Text]
  10. Stoilov I., Akarsu A. N., Alozie I. Sequence analysis and homology modeling suggest that primary congenital glaucoma on 2p21 results from mutations disrupting either the hinge region or the conserved core structures of cytochrome P4501B1. Am. J. Hum. Genet., 62: 573-584, 1998.[Medline]
  11. Bejjani B. A., Lewis R. A., Tomey K. F., Anderson K. L., Dueker D. K., Jabak M., Astle W. F., Otterud B., Leppert M., Lupski J. R. Mutations in CYP1B1, the gene for cytochrome P4501B1, are the predominant cause of primary congenital glaucoma in Saudi Arabia. Am. J. Hum. Genet., 62: 325-333, 1998.[Medline]
  12. Sasaki M., Dharia A., Oh B. R., Tanaka Y., Fujimoto S., Dahiya R. Progesterone receptor B gene inactivation and CpG hypermethylation in human uterine endometrial cancer. Cancer Res., 61: 97-102, 2001.[Abstract/Free Full Text]
  13. Sutter T. R., Tang Y. M., Hayes C. L., Wo Y. P., Jabs E. W., Li X., Yin H., Cody C. W., Greenlee W. F. Complete cDNA sequence of a human dioxin-inducible mRNA identifies a new gene subfamily of cytochrome P450 that maps to chromosome 2. J. Biol. Chem., 269: 13092-13099, 1994.[Abstract/Free Full Text]
  14. Cavalieri E. L., Stack D. E., Devanesan P. D., Todorvic R., Dwivedy I., Higginbotham S., Johansson S. L., Patil K. D., Gross M. L., Gooden J. K., Ramanathan R., Cerny R. L. Molecular origin of cancer: catechol estrogen-3, 4-quinones as endogenous tumor initiators. Proc. Natl. Acad. Sci. USA, 94: 10937-10942, 1997.[Abstract/Free Full Text]
  15. Liehr J. G. Catecholestrogens in the induction of tumors in the kidney of the Syrian hamster. Adv. Pharmacol., 42: 824-828, 1998.
  16. Jefcoate C. R., Liehr J. G., Santen R. J., Sutter T. R., Yager J. D., Yue W., Santner S. J., Tekmal R., Demers L., Pauley R., Naftolin F., Mor G., Berstein L. Tissue-specific synthesis and oxidative metabolism of estrogens. J. Natl. Cancer Inst. Monogr., 2000: 95-112, 2000.[Abstract/Free Full Text]
  17. Cavalieri E., Frenkel K., Liehr J. G., Rogan E., Roy D. Estrogens as endogenous genotoxic agents—DNA adducts and mutations. J. Natl. Cancer Inst. Monogr., 2000: 75-93, 2000.[Abstract/Free Full Text]
  18. Shimada T., Hayes C. L., Yamazaki H., Amin S., Hecht S. S., Guengerich F. P., Sutter T. R. Activation of chemically diverse procarcinogens by human cytochrome P-450 1B1. Cancer Res., 56: 2979-2984, 1996.[Abstract/Free Full Text]
  19. Lee K. M., Abel J., Ko Y., Harth V., Park W. Y., Seo J. S., Yoo K. Y., Choi J. Y., Shin A., Ahn S. H., Noh D. Y., Hirvonen A., Kang D. Genetic polymorphisms of cytochrome P450 19 and 1B1, alcohol use, and breast cancer risk in Korean women. Br. J. Cancer, 88: 675-678, 2003.[Medline]
  20. Schutze N., Vollmer G., Tiemann I., Geiger M., Knuppen R. Catecholestrogens are MCF-7 cell estrogen receptor agonists. J. Steroid Biochem. Mol. Biol., 46: 781-789, 1993.[Medline]



This article has been cited by other articles:


Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
X. Yuan, G. Zhou, Y. Zhai, W. Xie, Y. Cui, J. Cao, L. Zhi, H. Zhang, H. Yang, X. Zhang, et al.
Lack of Association between the Functional Polymorphisms in the Estrogen-Metabolizing Genes and Risk for Hepatocellular Carcinoma
Cancer Epidemiol. Biomarkers Prev., December 1, 2008; 17(12): 3621 - 3627.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
T. R. Rebbeck, A. B. Troxel, E. G. Shatalova, R. Blanchard, S. Norman, G. Bunin, A. DeMichele, R. Schinnar, J. A. Berlin, and B. L. Strom
Lack of Effect Modification between Estrogen Metabolism Genotypes and Combined Hormone Replacement Therapy in Postmenopausal Breast Cancer Risk
Cancer Epidemiol. Biomarkers Prev., June 1, 2007; 16(6): 1318 - 1320.
[Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
T. R. Rebbeck, A. B. Troxel, A. H. Walker, S. Panossian, S. Gallagher, E. G. Shatalova, R. Blanchard, S. Norman, G. Bunin, A. DeMichele, et al.
Pairwise Combinations of Estrogen Metabolism Genotypes in Postmenopausal Breast Cancer Etiology
Cancer Epidemiol. Biomarkers Prev., March 1, 2007; 16(3): 444 - 450.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
M. H. Tao, Q. Cai, W. H. Xu, N. Kataoka, W. Wen, W. Zheng, Y. B. Xiang, Z.-F. Zhang, and X. O. Shu
Cytochrome P450 1B1 and Catechol-O-Methyltransferase Genetic Polymorphisms and Endometrial Cancer Risk in Chinese Women
Cancer Epidemiol. Biomarkers Prev., December 1, 2006; 15(12): 2570 - 2573.
[Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
T. R. Rebbeck, A. B. Troxel, Y. Wang, A. H. Walker, S. Panossian, S. Gallagher, E. G. Shatalova, R. Blanchard, G. Bunin, A. DeMichele, et al.
Estrogen sulfation genes, hormone replacement therapy, and endometrial cancer risk.
J Natl Cancer Inst, September 20, 2006; 98(18): 1311 - 1320.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
T. M. Sissung, D. K. Price, A. Sparreboom, and W. D. Figg
Pharmacogenetics and Regulation of Human Cytochrome P450 1B1: Implications in Hormone-Mediated Tumor Metabolism and a Novel Target for Therapeutic Intervention
Mol. Cancer Res., March 1, 2006; 4(3): 135 - 150.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Boyd
Genetic Basis of Familial Endometrial Cancer: Is There More to Learn?
J. Clin. Oncol., July 20, 2005; 23(21): 4570 - 4573.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
E. Aklillu, S. Ovrebo, I. V. Botnen, C. Otter, and M. Ingelman-Sundberg
Characterization of Common CYP1B1 Variants with Different Capacity for Benzo[a]pyrene-7,8-Dihydrodiol Epoxide Formation from Benzo[a]pyrene
Cancer Res., June 15, 2005; 65(12): 5105 - 5111.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
J. A. Doherty, N. S. Weiss, R. J. Freeman, D. A. Dightman, P. J. Thornton, J. R. Houck, L. F. Voigt, M. A. Rossing, S. M. Schwartz, and C. Chen
Genetic Factors in Catechol Estrogen Metabolism in Relation to the Risk of Endometrial Cancer
Cancer Epidemiol. Biomarkers Prev., February 1, 2005; 14(2): 357 - 366.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
S. Bandiera, S. Weidlich, V. Harth, P. Broede, Y. Ko, and T. Friedberg
Proteasomal Degradation of Human CYP1B1: Effect of the Asn453Ser Polymorphism on the Post-Translational Regulation of CYP1B1 Expression
Mol. Pharmacol., February 1, 2005; 67(2): 435 - 443.
[Abstract] [Full Text] [PDF]

Home page
 Mol Hum ReprodHome page
Y. Saijo, F. Sata, H. Yamada, K. Suzuki, S. Sasaki, T. Kondo, Y.Y. Gong, E.H. Kato, S. Shimada, M. Morikawa, et al.
Ah receptor, CYP1A1, CYP1A2 and CYP1B1 gene polymorphisms are not involved in the risk of recurrent pregnancy loss
Mol. Hum. Reprod., October 1, 2004; 10(10): 729 - 733.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
T. Rylander-Rudqvist, S. Wedren, G. Jonasdottir, S. Ahlberg, E. Weiderpass, I. Persson, and M. Ingelman-Sundberg
Cytochrome P450 1B1 Gene Polymorphisms and Postmenopausal Endometrial Cancer Risk
Cancer Epidemiol. Biomarkers Prev., September 1, 2004; 13(9): 1515 - 1520.
[Abstract] [Full Text] [PDF]

Home page
 J. Med. Genet.Home page
R Melki, E Colomb, N Lefort, A P Brezin, and H-J Garchon
CYP1B1 mutations in French patients with early-onset primary open-angle glaucoma
J. Med. Genet., September 1, 2004; 41(9): 647 - 651.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
M. McGrath, S. E. Hankinson, L. Arbeitman, G. A. Colditz, D. J. Hunter, and I. De Vivo
Cytochrome P450 1B1 and catechol-O-methyltransferase polymorphisms and endometrial cancer susceptibility
Carcinogenesis, April 1, 2004; 25(4): 559 - 565.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sasaki, M.
Right arrow Articles by Dahiya, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sasaki, M.
Right arrow Articles by Dahiya, R.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online